A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid-Formoterol Inhalers in Asthma
Name:
CLEAN_FINAL _ASTHMA SPECIAL ISSUE ...
Size:
2.496Mb
Format:
PDF
Description:
Final Accepted Manuscript
Author
Krings, James GGerald, Joe K
Blake, Kathryn V
Krishnan, Jerry A
Reddel, Helen K
Bacharier, Leonard B
Dixon, Anne E
Sumino, Kaharu
Gerald, Lynn B
Brownson, Ross C
Persell, Stephen D
Clemens, Conrad J
Hiller, Katherine M
Castro, Mario
Martinez, Fernando D
Affiliation
Department of Community Environment and Policy, Mel and Enid Zuckerman College of Public Health, Asthma & Airway Disease Research Center, University of ArizonaAsthma & Airway Disease Research Center, University of Arizona
Department of Pediatrics, University of Arizona
Issue Date
2023-02-15Keywords
Asthmaimplementation science
asthma morbidity
inhalers
symptom driven asthma management
formoterol
over-the-counter medication usage
Metadata
Show full item recordPublisher
The American Thoracic Society (ATS)Citation
Krings, J. G., Gerald, J. K., Blake, K. V., Krishnan, J. A., Reddel, H. K., Bacharier, L. B., ... & Martinez, F. D. (2023). A call for the United States to accelerate the implementation of reliever combination inhaled corticosteroid–formoterol inhalers in asthma. American journal of respiratory and critical care medicine, 207(4), 390-405.Rights
© 2023 by the American Thoracic Society.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Asthma management has undergone a paradigm shift that is underutilized by real-world clinicians, particularly in the United States (US). Trials containing approximately 30,000 patients over 20 years have demonstrated the benefits of new inhaler approaches. In mild asthma, reliever usage of an inhaled corticosteroid (ICS) with formoterol (a unique rapid-onset long-acting β-agonist) provides quick symptom relief and is substantially more effective at preventing asthma exacerbations than short-acting β-agonist (SABA) monotherapy. In moderate/severe asthma using an ICS-formoterol inhaler on both a maintenance and reliever basis (single maintenance and reliever therapy [SMART]) is more effective at preventing severe exacerbations than traditional asthma management. As a result, the Global Initiative for Asthma (GINA) now calls for the preferential use of ICS-formoterol inhalers on a reliever basis at all steps of management. The US-based National Asthma Education and Prevention Program (NAEPP) guideline published in 2020 did not review as-needed ICS-formoterol in mild asthma, but similarly recommends SMART at Steps 3-4 within their management paradigm. In this article we review the latest asthma recommendations and the rationale for the recommendation/guideline changes. We then acknowledge and name the barriers to utilizing these new inhaler approaches that exist in real-world practice, particularly in the US. Using the tools of implementation science, we call for the asthma field to urgently work to ameliorate these barriers . Finally, while admittedly controversial, we call for consideration of the prescription-to-over-the-counter transition of low-dose budesonide formoterol in the US. This transition could expand medication access, reduce unopposed use of SABAs, and provide a more acceptable safety net for patients, as compared to aerosolized epinephrine, which is currently the only available OTC reliever inhaler in the US.Note
12 month embargo; first published 15 February 2023EISSN
1535-4970PubMed ID
36538711Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1164/rccm.202209-1729PP
Scopus Count
Collections
Related articles
- Beginning to Address an Implementation Gap in Asthma: Clinicians' Views of Prescribing Reliever Budesonide-Formoterol Inhalers and SMART in the United States.
- Authors: Krings JG, Sekhar TC, Chen V, Blake KV, Sumino K, James AS, Clover AK, Lenze EJ, Brownson RC, Castro M
- Issue date: 2023 Sep
- Satisfaction with single maintenance and reliever therapy or as-needed combined inhaled corticosteroid-formoterol in adults with asthma.
- Authors: LaCava AF, Gleeson PK, Apter AJ
- Issue date: 2023 Mar
- ICS/formoterol maintenance and reliever therapy: how far beyond asthma?
- Authors: Beasley R, Bruce P, Hatter L
- Issue date: 2023 May
- Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma.
- Authors: McCormack PL, Lyseng-Williamson KA
- Issue date: 2007
- The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.
- Authors: Beasley R, Bruce P, Houghton C, Hatter L
- Issue date: 2023 Mar